LMWH (Low-molecular-weight heparin)
Category: Pharmaceutical and Medical
Exhibitor: BIONOVAX CORP
Booth No: M928
Enoxaparin is a low-molecular weight heparin (LMWH) derived from the cleavage of unfractionated heparin (UFH). Its molecular weight ranges from 2000 to 8000 Da (average molecular weight of 3800 to 5000 Da). In clinical use, it exhibits several advantages compared with UFH, such as better injection and absorption, longer half-life of efficacy, higher bio-availability (BA), less bleeding and no need to perform APTT assay on the patients by periods of treatment (APTT, Activated Partial thromboplastin time, which is a necessary laboratory method for continuously monitoring the patient's use of UFH due to the risk of severe bleeding caused by high doses). The treatment of deep vein thrombosis and pulmonary embolism is also more effective than UFH.
Our LMWH (Enoxaparin) is manufactured from API pharmaceutical factory complied with PIC/S GMP standards. Therefore, our LMWH possesses high quality, stable activity, and meet the internationally recognized USP and EP standards to provide downstream drug-product pharmaceutical manufacturer for developing various doses of injection-type products.
Products you may be interested in